STOCKHOLM, Sweden--(BUSINESS WIRE)--Medivir (STO:MVIRB) has filed an application with a European regulatory authority to commence phase I clinical trials with MIV-701, an inhibitor of cathepsin K. The trials are expected to start in Q1/2007.
STOCKHOLM, Sweden--(BUSINESS WIRE)--Medivir (STO:MVIRB) has filed an application with a European regulatory authority to commence phase I clinical trials with MIV-701, an inhibitor of cathepsin K. The trials are expected to start in Q1/2007.